GlassScriptPhysician profile
Molly Sandgren
NPI 1669981296
$1,558.12
in general payments reported to CMS, 2019-2025
11 companies · $550 in 2025
The $550 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $385 · 2024: $514 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.23 | 2022-2024 | Jardiance |
| Amgen INC. | $343.41 | 2024-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $180.43 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $146.81 | 2025 | Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $124.80 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.12 | 2023 | |
| Myriad Women'S Health, INC. | $102.71 | 2023 | Myrisk |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.55 | 2024 | Lifevest |
| Lilly USA, LLC | $38.23 | 2023-2024 | Mounjaro |
| Abbvie INC. | $31.63 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.20 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Sandgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.